LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

    Watanabe, Tatsuro / Yamamoto, Yuta / Kurahashi, Yuki / Kawasoe, Kazunori / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Nakamura, Hideaki / Okada, Seiji / Sueoka, Eisaburo / Kimura, Shinya

    Blood advances

    2024  Volume 8, Issue 6, Page(s) 1345–1358

    Abstract: Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine- ... ...

    Abstract Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine-cytidine kinase 2 (UCK2), which supports vigorous proliferation. UCK2 catalyzes the monophosphorylation of cytidine/uridine and their analogues during pyrimidine biosynthesis and drug metabolism. We found that UCK2 was overexpressed aberrantly in HTLV-1-infected T cells but not in normal T cells. T-cell activation via T-cell receptor (TCR) signaling induced expression of UCK2 in normal T cells. Somatic alterations and epigenetic modifications in ATL cells activate TCR signaling. Therefore, we believe that expression of UCK2 in HTLV-1-infected cells is induced by dysregulated TCR signaling. Recently, we established azacitidine-resistant (AZA-R) cells showing absent expression of UCK2. AZA-R cells proliferated normally in vitro, whereas UCK2 knockdown inhibited ATL cell growth. Although uridine and cytidine accumulated in AZA-R cells, possibly because of dysfunction of pyrimidine salvage biosynthesis induced by loss of UCK2 expression, the amount of UTP and CTP was almost the same as in parental cells. Furthermore, AZA-R cells were more susceptible to an inhibitor of dihydroorotic acid dehydrogenase, which performs the rate-limiting enzyme of de novo pyrimidine nucleotide biosynthesis, and more resistant to dipyridamole, an inhibitor of pyrimidine salvage biosynthesis, suggesting that AZA-R cells adapt to UCK2 loss by increasing de novo pyrimidine nucleotide biosynthesis. Taken together, the data suggest that fine-tuning pyrimidine biosynthesis supports vigorous cell proliferation of both normal T cells and ATL cells.
    MeSH term(s) Adult ; Humans ; Pyrimidines ; Uridine/metabolism ; Cell Proliferation ; Cytidine ; Human T-lymphotropic virus 1 ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell ; T-Lymphocytes/metabolism
    Chemical Substances Pyrimidines ; Uridine (WHI7HQ7H85) ; Cytidine (5CSZ8459RP) ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2024-01-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023011131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

    Kamachi, Kazuharu / Ureshino, Hiroshi / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Kawasoe, Kazunori / Hoshiko, Toshimi / Yamamoto, Yuta / Kurahashi, Yuki / Kimura, Shinya

    Cancer research communications

    2023  Volume 3, Issue 2, Page(s) 297–308

    Abstract: The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high ... ...

    Abstract The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high response rates, and potentially durable remission; however, because of low oral bioavailability, these conventional HMAs must be administered intravenously or subcutaneously. A combination of oral HMAs and Ven would provide a therapeutic advantage over parenteral administration of drugs and improve quality of life by reducing the number of hospital visits. Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21). Here, we investigated the efficacy and underlying mechanism of OR21 when used in combination with Ven to treat AML. OR21/Ven showed synergistic antileukemia effects
    Significance: The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects
    MeSH term(s) Humans ; Animals ; Mice ; Aged ; Quality of Life ; Azacitidine/pharmacology ; Antineoplastic Agents/pharmacology ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances venetoclax (N54AIC43PW) ; Azacitidine (M801H13NRU) ; Antineoplastic Agents
    Language English
    Publishing date 2023-02-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.CRC-22-0259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

    Kawasoe, Kazunori / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Yamamoto, Yuta / Kurahashi, Yuki / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Fukuda-Kurahashi, Yuki / Kimura, Shinya

    Cancers

    2023  Volume 15, Issue 20

    Abstract: The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in ... ...

    Abstract The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in non-small cell lung carcinoma (NSCLC). Since
    Language English
    Publishing date 2023-10-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15205089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top